Cutivate克廷膚

Cutivate Dosage/Direction for Use

fluticasone

Manufacturer:

GlaxoSmithKline

Distributor:

Zuellig
/
Agencia Lei Va Hong
Full Prescribing Info
Dosage/Direction for Use
Creams are especially appropriate for moist or weeping surfaces.
Adults, children and infants aged 3 months and over: Treatment of inflammatory dermatoses: Apply a thin layer and gently rub in using only enough to cover the entire affected area. Perform the treatment once or twice daily for up to 4 weeks until improvement occurs, then reduce the frequency of application or change the treatment to a less potent preparation. Allow adequate time for absorption after each application before applying an emollient. If the condition worsens or does not improve within 2-4 weeks, treatment and diagnosis should be re-evaluated.
Atopic dermatitis: Therapy with topical corticosteroids should be gradually discontinued once control is achieved and an emollient continued as maintenance therapy.
Rebound of pre-existing dermatoses can occur with abrupt discontinuation of topical steroids especially with potent preparations.
Reduction of the risk of relapse: Once an acute episode has been treated effectively, application frequency should be reduced to once daily application, twice weekly, without occlusion. Application should be continued to all previously affected sites or to known sites of potential relapse. This regime should be combined with routine daily use of emollients. The condition must be re-evaluated on a regular basis.
Paediatric population: Children over 3 months: Children are more likely to develop local and systemic side effects of topical corticosteroids and, in general, require shorter courses and less potent agents than adults.
Safety and efficacy of the product for longer than 4 weeks in paediatric patients is not established.
Care should be taken when using fluticasone propionate to ensure the amount applied is the minimum that provides therapeutic benefit.
Elderly: Clinical studies have not identified differences in responses between the elderly and younger patients. The greater frequency of decreased hepatic or renal function in the elderly may delay elimination if systemic absorption occurs. Therefore the minimum quantity should be used for the shortest duration to achieve the desired clinical benefit.
Renal / Hepatic Impairment: In case of systemic absorption (when application is over a large surface area for a prolonged period) metabolism and elimination may be delayed therefore increasing the risk of systemic toxicity. Therefore the minimum quantity should be used for the shortest duration to achieve the desired clinical benefit.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in